Here's What Key Metrics Tell Us About Agilon (AGL) Q3 Earnings

Core Insights - Agilon Health (AGL) reported $1.45 billion in revenue for Q3 2024, a year-over-year increase of 19.4% [1] - The EPS for the same period was -$0.29, compared to -$0.06 a year ago, indicating a significant decline [1] - Revenue fell short of the Zacks Consensus Estimate of $1.47 billion by 1.29%, while the EPS surprise was -190.00% against the consensus estimate of -$0.10 [1] Financial Metrics - Average Medicare Advantage membership reached 535,000, exceeding the average estimate of 514,093 based on two analysts [3] - Revenue from medical services was $1.45 billion, compared to the estimated $1.47 billion by six analysts, reflecting a 19.4% increase year-over-year [3] - Revenue from other operating activities was $3.24 million, slightly below the estimated $3.27 million, showing an 8.3% decline compared to the previous year [3] Stock Performance - Agilon's shares have returned -7.7% over the past month, contrasting with the Zacks S&P 500 composite's +3.2% change [4] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [4]